SynthesisFrontiers in oncology2026
Global research landscape of ferroptosis in colorectal cancer: a multi-database bibliometric analysis (2017-2025).
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ferroptosis, an iron-dependent form of regulated cell death, has attracted increasing attention in recent years because of its critical roles in tumor progression, therapeutic resistance, and immune regulation. Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide and imposes a substantial mortality burden. This study aimed to systematically analyze the global research landscape, hotspots, and developmental trends of ferroptosis in CRC research from 2017 to 2025. Methods: English-language publications related to ferroptosis and CRC published between January 1, 2017, and December 31, 2025, were retrieved from the Web of Science Core Collection (WoSCC) and Scopus databases. A total of 1, 354 original articles and reviews were included. VOSviewer, CiteSpace, and the bibliometrix package in R were used for bibliometric and visualization analyses to evaluate annual publication trends, country/region and institutional collaboration networks, author contributions, journal distribution, co-cited references, keyword co-occurrence, and thematic evolution. Results: The number of publications in this field increased rapidly after 2020 and peaked in 2025. China ranked first in both publication output and total citations, followed by the United States, and China-United States collaboration constituted the core of the international collaboration network. Central South University was the most productive institution, while journals such as Frontiers in Oncology and Frontiers in Immunology served as major publication platforms. Research hotspots were mainly concentrated on chemotherapy resistance, the tumor immune microenvironment, PANoptosis, prognostic models, non-coding RNAs, gut microbiota, and the regulation of ferroptosis by traditional Chinese medicine and natural products. Conclusion: Ferroptosis has become a rapidly evolving frontier in CRC research. The research focus is gradually shifting from fundamental molecular mechanisms toward translational medical directions, including chemosensitization, combination immunotherapy, reversal of drug resistance, and precise prognostic evaluation. This study provides a systematic reference for understanding the global knowledge structure and future research directions in the field of ferroptosis and CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.